Gabriela Morales-Rivera is an associate in the firm's Business Law Department and a member of its Technology & Life Sciences group. Ms. Morales-Rivera represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.

She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Ms. Morales-Rivera has worked with many of her company-side clients since their initial founding and funding. She joined Goodwin in 2015.

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Ms. Morales-Rivera’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

  • Akero Therapeutics in its $65 million Series A financing
  • Aptinyx in connection with:
    • its $65 million Series A financing
    • its $70 million Series B financing
    • its $117.8 million initial public offering
  • Exosome Diagnostics in connection with:
    • its $30 million Series C financing
    • its sale to Bio-Techne Corporation
  • Kymera Therapeutics in its $30 million Series A financing
  • Neon Therapeutics in connection with:
    • its $106 million Series B financing
    • its $100 million initial public offering
  • Nimbus Therapeutics in connection with:
    • the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
    • its multi-target strategic alliance with Celgene Corporation in immunology
    • its $65 million Series 2018 preferred stock financing
  • Relay Therapeutics in its $63 million Series B financing
  • SmileDirectClub in its $380 million financing
  • Tango Therapeutics in its $55 million Series A financing

Public Company Representation and Capital Markets Transactions

  • Intellia Therapeutics in its $150.0 million follow-on offering
  • Sage Therapeutics in its $575 million and $345 million follow-on offering
  • Repligen Corp. in connection with:
    • its acquisition of TangenX Technology Corporation
    • its acquisition of Spectrum, Inc.
    • its $138 million follow-on offering
  • resTORbio in its $97.8 million initial public offering
Professional Experience

While attending law school, Ms. Morales-Rivera interned for the Honorable Juan R. Torruella of the First Circuit Court of Appeals.

Ms. Morales-Rivera is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2015
Boston University School of Law
B.A., 2012
Swarthmore College
(with high honors)

Admissions

Bar

Massachusetts
Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师